Full-Time

Quality Control Manager

Analytical Stability

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

Compensation Overview

$120k - $150k/yr

San Diego, CA, USA

In Person

Occasional travel between San Diego, CA and Bristol, PA.

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree or higher in Chemistry, Biology, or related Life Sciences discipline
  • Minimum 10 years of experience in QC GMP pharmaceutical or biotechnology laboratories within a cGMP-regulated environment
  • Minimum 5–6 years of people management experience in QC laboratory settings
  • Extensive knowledge of HPLC, SDS-PAGE, ELISA, Capillary Electrophoresis (CE), cIEF (Maurice platform), UV-Vis, cell-based potency assay, and compendial methods
  • Knowledge of ICH, European Pharmacopoeia (EP), United States Pharmacopeia (USP), and Food and Drug Administration guidelines relating to method development, qualification/validation, and stability studies
  • Excellent written, verbal, and interpersonal communication skills
  • Strong technical writing and documentation skills
  • Proficiency in Microsoft Word, Excel, and PowerPoint
  • Strong organizational skills with ability to manage multiple priorities in a fast-paced, deadline-driven environment
  • Ability to proactively communicate risks, issues, and solutions to management
  • Strong troubleshooting, problem-solving, and decision-making skills
  • Detail-oriented with strong analytical mindset
  • Ability to work independently while collaborating effectively across teams
  • Experience supporting controlled document generation, review, and approval processes
  • Ability to draft and review Certificates of Analysis and reagent specification documents
  • Flexibility to work adjusted hours based on business needs
Responsibilities
  • Leading analytical methods support activities related to stability testing, product control programs, and reference standard management
  • Oversee daily operations of the QC Stability function in a biopharmaceutical manufacturing environment supporting multiple products and client programs
  • Drive continuous improvement and operational efficiency across stability workflows, systems, and processes
  • Ensure compliant operation and maintenance of stability-related infrastructure, documentation, equipment preventive maintenance, calibration, qualification, and training programs
  • Provide leadership, mentorship, and development opportunities for QC staff and associates
  • Ensure appropriate training of personnel in technical skills, cGMP compliance, data integrity, and safety requirements
  • Communicate departmental goals, priorities, and performance expectations to direct reports
  • Support facility teams in ensuring timely maintenance, calibration, and qualification of laboratory instruments and equipment
  • Manage and oversee stability study design, protocol development, execution, and lifecycle management
  • Coordinate stability protocol and report authoring in accordance with ICH guidelines, internal SOPs, and quality system requirements
  • Oversee stability study setup, including sample management, material staging, and fraction tracking
  • Track and monitor all active stability programs, including pull schedules, testing timelines, report completion, and Stability Summary Sheet issuance
  • Maintain accurate and current stability inventory records
  • Lead reference standard qualification, management, retesting, and lifecycle activities
  • Monitor inventory, testing schedules, stability requirements, and timely issuance of associated certificates
  • Provide training and oversight for laboratory personnel supporting reference standard activities
  • Represent QC Stability in internal meetings, client meetings, audits, and cross-functional discussions related to stability and reference standards
  • Ensure compliant analytical laboratory support and resource planning
  • Author and/or review deviations, investigations, CAPAs, change controls, and risk assessments related to stability and reference standard programs
  • Support or lead investigations involving OOS, OOT, non-conformances, and laboratory events
  • Review analytical data packages, perform data trending, and provide troubleshooting support for complex laboratory issues
  • Partner closely with Manufacturing, Analytical Development, Tech Transfer, Regulatory, and Quality Assurance teams
  • Support strategic planning for new equipment, staff capacity planning, organizational structure, and resource requirements
  • Recommend and justify additional equipment, staffing, promotions, or organizational changes as needed
  • Occasional travel may be required between Abzena sites, including San Diego, California and Bristol, Pennsylvania

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Geoffrey M. Glass appointed CEO July 22, 2025, drives growth.
  • Dr. Moncef Slaoui joins board January 8, 2025, boosts innovation.
  • Scientific Advisory Board formed May 15, 2025, guides ADC strategies.

What critics are saying

  • Lonza acquires Halo Life Science March 17, 2026, steals ADC share.
  • WuXi Biologics launches 10 ADC technologies Q1 2026, undercuts ThioBridge®.
  • FDA warning letter halts Bristol PA trials January 15, 2026.

What makes Abzena unique

  • ThioBridge® platform creates stable, effective ADCs for clients.
  • Composite Human Antibody™ reduces immunogenicity in biologics.
  • AbZelectPRO™ launches GS knockout CHO-K1 for afucosylated proteins.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Abzena who can refer or advise you

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth

Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.